$32.88
Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down
Overview
52-week range
$14
$45
62% of range
Avg surprise (last 3)
+0.4%
Avg reaction (last 2)
+8.1%
100% positive
Latest IV / EM
116%
EM ±18.1% · $35 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.77 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-1.46 | $-1.37 | -6.6% | -82.5% | +4.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.22 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-1.25 | $-1.02 | -22.6% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.80 | $-1.15 | +30.4% | — | +12.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-5.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-24.23 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-17.89 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.96 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | — | — | $0 | $0 | $10M | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-108M | $-77M | — | $-53M | $-55M | $-37M | — | $-41M |
| Net income | $-111M | $-81M | — | $-51M | $-52M | $-34M | — | $-39M |
| EPS (diluted) | $-1.77 | $-1.46 | — | $-1.22 | $-1.25 | $-0.80 | — | $-5.02 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $197M | $500M | $111M | $116M | $44M | $197M | $320M | $360M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $654M | $730M | $351M | $297M | $279M | $318M | $356M | $394M |
| Total assets | $702M | $748M | $384M | $322M | $293M | $334M | $370M | $403M |
| Long-term debt | — | — | — | $73M | — | — | — | — |
| Total liabilities | $455M | $412M | $141M | $126M | $53M | $49M | $58M | $44M |
| Total equity | $247M | $336M | $242M | $196M | $240M | $284M | $312M | $359M |